Aktis Oncology(AKTS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AKTS Aktis Oncology

Pre-Mkt 07-02 05:15:19 EDT

30.89

-1.34

-4.16%

High32.31	Low30.86	Vol536.87K
Open31.96	D1 Closing32.23	Amplitude4.49%
Mkt Cap1.71B	Tradable Cap545.21M	Total Shares55.28M
T/O16.83M	T/O Rate3.04%	Tradable Shares17.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AKTS","market":"US","secType":"STK","nameCN":"Aktis Oncology","latestPrice":30.89,"timestamp":1782936000000,"preClose":32.23,"halted":0,"volume":536865,"delay":0,"changeRate":-0.041576171269003925,"floatShares":17650000,"shares":55276000,"eps":-1.213,"marketStatus":"Pre-Mkt","change":-1.34,"latestTime":"07-02 05:15:19 EDT","open":31.96,"high":32.3066,"low":30.86,"amount":16831353.935025,"amplitude":0.044884,"askPrice":49.11,"askSize":100,"bidPrice":30.89,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-1.213,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1782999000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1767934800000,"exchange":"NASDAQ","adjPreClose":30.89,"postHourTrading":{"tag":"盘后","latestPrice":30.5,"preClose":30.89,"latestTime":"19:58 EDT","volume":25604,"amount":790973.56,"timestamp":1782950311411,"change":-0.39,"changeRate":-0.012625,"amplitude":0.029136},"volumeRatio":0.6236368307926089,"impliedVol":1.5345,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/AKTS","defaultTab":"news","newsList":[{"id":"2643773247","title":"U.S. RESEARCH ROUNDUP-CAMP4 Therapeutics, Rockwell Automation, Zions Bancorporation","url":"https://stock-news.laohu8.com/highlight/detail?id=2643773247","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643773247?lang=en_us&edition=fundamental","pubTime":"2026-06-16 16:11","pubTimestamp":1781597519,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-CAMP4 Therapeutics, Rockwell Automation, Zions BancorporationJune 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nL8N42O0EI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COHU","PLAY","IE0002141913.USD","INSM","KRYS","CFG","EMR","KMX","BK4147","BDC","FCEL","ELF","CSR","AMGN","FICO","XOMX","BETR","LU1150488218.USD","HBAN","ESAB","XOM","BK4533","KMT","FITB","DT","HWM","FOXA","LEN","LU0029874061.USD","EXR","ZION","CAMP","XOMO","CCL","KRC","AKTS","BK4159","BBIO","FLUT","HPP","XOMZ","CVLT","AIT","EFX","KEY","MSM","GPC","FAST","ROKU","DOMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643978512","title":"Aktis Oncology initiated with a Strong Buy at Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2643978512","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643978512?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:12","pubTimestamp":1781554330,"startTime":"0","endTime":"0","summary":"Raymond James analyst Christopher Raymond initiated coverage of Aktis Oncology (AKTS) with a Strong Buy rating and $40 price target The firm thinks...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aktis-oncology-initiated-with-a-strong-buy-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aktis-oncology-initiated-with-a-strong-buy-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU1363072403.SGD","AKTS","BK4148","IE00BGHQF748.EUR","LU0971096721.USD","BK4585","IE00B3QW5Z07.USD","LU2265009873.SGD","IE00B64PRP62.GBP","BK4588","LU1804176565.USD","RJF","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642478843","title":"Aktis Oncology posts investor presentation on miniprotein radioconjugate platform, lead Nectin-4 and B7-H3 programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2642478843","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642478843?lang=en_us&edition=fundamental","pubTime":"2026-06-11 01:13","pubTimestamp":1781111585,"startTime":"0","endTime":"0","summary":"Lead asset AKY-1189 targets Nectin-4 tumors; Phase 1b is ongoing with preliminary data expected in 1Q 2027.Second program AKY-2519 targets B7-H3; Phase 1b in mCRPC started in 2Q 2026 with preliminary data expected in 2027.A B7-H3 basket Phase 1b trial is slated to start in 2H 2026, expanding into lung, colorectal, and other solid tumors.Manufacturing scale-up remains a near-term focus, with an in-house GMP suite expected to be operational in 2H 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aktis Oncology Inc. published the original content used to generate this news brief on June 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL2yjHYb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AKTS","BK4148"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640067942","title":"Aktis Oncology Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2640067942","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640067942?lang=en_us&edition=fundamental","pubTime":"2026-06-03 01:09","pubTimestamp":1780420140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AKTS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 02, 2026 13:09 ET (17:09 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640421429","title":"Aktis Oncology price target raised to $35 from $33 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2640421429","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640421429?lang=en_us&edition=fundamental","pubTime":"2026-06-03 00:28","pubTimestamp":1780417724,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Robert Burns raised the firm’s price target on Aktis Oncology (AKTS) to $35 from $33 and keeps a Buy rating on the shares a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aktis-oncology-price-target-raised-to-35-from-33-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aktis-oncology-price-target-raised-to-35-from-33-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AKTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640441589","title":"Aktis Oncology, Inc. : H.c. Wainwright Raises Target Price to $35 From $33","url":"https://stock-news.laohu8.com/highlight/detail?id=2640441589","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640441589?lang=en_us&edition=fundamental","pubTime":"2026-06-02 23:44","pubTimestamp":1780415080,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nAZN4T02Q6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4148","BK4139","AKTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638318586","title":"Analyst Reiterates Buy on Aktis Oncology, Maintains $34 Price Target Following Encouraging AKY-2519 ASCO Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2638318586","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638318586?lang=en_us&edition=fundamental","pubTime":"2026-05-28 05:16","pubTimestamp":1779916581,"startTime":"0","endTime":"0","summary":"Alec Stranahan, an analyst from Bank of America Securities, maintained the Buy rating on Aktis Oncology, Inc.. The associated price target remains ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-aktis-oncology-maintains-34-price-target-following-encouraging-aky-2519-asco-update-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-aktis-oncology-maintains-34-price-target-following-encouraging-aky-2519-asco-update-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AKTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638635035","title":"Aktis Oncology CEO to present at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2638635035","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638635035?lang=en_us&edition=fundamental","pubTime":"2026-05-28 04:18","pubTimestamp":1779913122,"startTime":"0","endTime":"0","summary":"Aktis Oncology will present at the Jefferies Global Healthcare Conference in New York on June 3, 2026, at 4:20 p.m. ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aktis Oncology Inc. published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDLDX0jl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4148","AKTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638684557","title":"Aktis Oncology Initiated at Buy on Promising AKY-2519 Safety Profile and Broad B7‑H3 Radiopharma Market Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2638684557","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638684557?lang=en_us&edition=fundamental","pubTime":"2026-05-27 23:35","pubTimestamp":1779896133,"startTime":"0","endTime":"0","summary":"William Blair analyst Alexandra Ramsey has reiterated their bullish stance on AKTS stock, giving a Buy rating on May 22. Alexandra Ramsey’s rating ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/aktis-oncology-initiated-at-buy-on-promising-aky-2519-safety-profile-and-broad-b7h3-radiopharma-market-opportunity-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/aktis-oncology-initiated-at-buy-on-promising-aky-2519-safety-profile-and-broad-b7h3-radiopharma-market-opportunity-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AKTS","BK4148"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638586500","title":"Aktis Oncology posts presentation on AKY-2519 clinical imaging, dosimetry data for B7-H3-targeted radioconjugate","url":"https://stock-news.laohu8.com/highlight/detail?id=2638586500","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638586500?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:14","pubTimestamp":1779884043,"startTime":"0","endTime":"0","summary":"Aktis Oncology presented first-in-human imaging, biodistribution, and dosimetry for B7-H3 radioconjugate AKY-2519 across advanced solid tumors.Early dataset showed no reported adverse events or infusion-related reactions, supporting continued clinical development.Dosimetry suggested high tumor absorbed doses with low predicted exposure to critical organs, indicating a potentially wide therapeutic index for actinium-225 therapy in mCRPC.Imaging in 34 patients showed lesion detection consistent with PSMA-11 in prostate cancer, with uptake also seen in lung cancers and colorectal cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aktis Oncology Inc. published the original content used to generate this news brief on May 27, 2026, and i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL3qhhhH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4148","BK4139","AKTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637631645","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2637631645","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637631645?lang=en_us&edition=fundamental","pubTime":"2026-05-22 19:18","pubTimestamp":1779448694,"startTime":"0","endTime":"0","summary":"PicoCELA  shares were up 172% in Friday premarket activity, extending Thursday's 60% rally.Leifras  stock was 113% higher after the company agreed to acquire Tokai Sports.Akari Therapeutics  shares were up 64% after the company reported positive preclinical data for its AKTX-101 investigational drug candidate.MetaVia  stock was 40% higher following a muted session.HCW Biologics  shares were up 25% after the company priced a private securities offering.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4020","BK4139","BK4204","AKTS","BK4539","MTVA","BK4148","BK7093","LFS.AU","LFS","BK4007","HCWB","AKTX","PCLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637949783","title":"Aktis Oncology (AKTS) Valuation Check After Recent Share Price Weakness And Lower Price To Book Ratio","url":"https://stock-news.laohu8.com/highlight/detail?id=2637949783","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637949783?lang=en_us&edition=fundamental","pubTime":"2026-05-22 15:38","pubTimestamp":1779435488,"startTime":"0","endTime":"0","summary":"Aktis Oncology stock: key recent moves\nAktis Oncology (AKTS) has drawn attention after recent trading left the stock at a last close of $19.12, with short term returns mixed and year to date performance currently showing a double digit decline.\nSee our latest analysis for Aktis Oncology.\nRecent trading shows momentum fading, with a 7 day share price return of 1.95% lower and a 30 day share price return of 6.73% lower, while the year to date share price return is 14.64% lower from the current...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-akts/aktis-oncology/news/aktis-oncology-akts-valuation-check-after-recent-share-price","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-akts/aktis-oncology/news/aktis-oncology-akts-valuation-check-after-recent-share-price","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AKTS","BK4148","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357765","title":"Aktis Oncology reports first-in-human AKY-2519 imaging data showing robust tumor uptake","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357765","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357765?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:39","pubTimestamp":1779399551,"startTime":"0","endTime":"0","summary":"Aktis Oncology released first-in-human imaging and dosimetry findings for its B7-H3-targeted radioconjugate AKY-2519, with data scheduled for presentation at the 2026 ASCO Annual Meeting on May 30.The readout showed strong tumor uptake with limited exposure in normal tissues across assessments in metastatic castration-resistant prostate cancer and a broader set of advanced solid tumors.The profile supported continued clinical development, including an ongoing Phase 1b study in mCRPC that includes PLUVICTO-nave and PLUVICTO-experienced patients, with preliminary data expected in 2027.A second Phase 1b study in other B7-H3-expressing solid tumors is planned to start in the second half of 2026, expanding the program beyond prostate cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL1ycsH3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKTS","BK4148","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637977357","title":"Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for Aky-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients With B7-H3 Expressing Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2637977357","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637977357?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:21","pubTimestamp":1779398468,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA8QPGQZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4148","AKTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634255803","title":"Analysts Are Bullish on Top Healthcare Stocks: Aktis Oncology, Inc. (AKTS), Metagenomi, Inc. (MGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634255803","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634255803?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:50","pubTimestamp":1778536214,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aktis Oncology, Inc. (AKTS), Metagenomi, Inc. (MGX) ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-aktis-oncology-inc-akts-metagenomi-inc-mgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-aktis-oncology-inc-akts-metagenomi-inc-mgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4585","XBI","BLSX","BLSG","BK4139","LU0029874061.USD","BK4581","LU0128526141.USD","MGX","AKTS","BK4148","BK4588","BK4112","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634253271","title":"Aktis Oncology reports Q1 revenue $3.23M, consensus $1.85M","url":"https://stock-news.laohu8.com/highlight/detail?id=2634253271","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634253271?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:36","pubTimestamp":1778535418,"startTime":"0","endTime":"0","summary":"Cash, cash equivalents and marketable securities were $538.5M as of March 31, compared to $226.8M as of December 31, 2025. “We continue to build mo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aktis-oncology-reports-q1-revenue-3-23m-consensus-1-85m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aktis-oncology-reports-q1-revenue-3-23m-consensus-1-85m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AKTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634253459","title":"Aktis Oncology Q1 EPS $(0.38) Beats $(0.44) Estimate, Sales $3.227M Beat $1.750M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2634253459","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634253459?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:35","pubTimestamp":1778535353,"startTime":"0","endTime":"0","summary":"Aktis Oncology (NASDAQ:AKTS) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.44) by 13.64 percent. This is a 97.96 percent increase over losses of $(18.60) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52472867/aktis-oncology-q1-eps-0-38-beats-0-44-estimate-sales-3-227m-beat-1-750m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Aktis Oncology Q1 EPS $(0.38) Beats $(0.44) Estimate, Sales $3.227M Beat $1.750M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634232223","title":"Aktis Oncology Q1 FY26 net loss widens to $18.3 million; revenue climbs to $3.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634232223","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634232223?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:06","pubTimestamp":1778529974,"startTime":"0","endTime":"0","summary":"Aktis Oncology posted a net loss of $18.3 million for first-quarter 2026, widening from a $15 million loss a year earlier.Collaboration revenue rose to $3.2 million from $1.4 million, on continued advancement of its research collaboration with Eli Lilly.R&D expenses climbed to $20 million from $15.9 million, while G&A costs increased to $5.9 million from $3.7 million.Cash, cash equivalents and marketable securities totaled $538.5 million at March 31, up from $226.8 million at year-end 2025, following gross IPO proceeds of about $365.4 million; cash runway expected into 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aktis Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data G","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDLqKvZg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","LU0820562030.AUD","LU1145028129.USD","LU1069344957.HKD","LU1280957306.USD","LU2237443622.USD","IE00BJJMRY28.SGD","IE00B1BXHZ80.USD","LU0823416689.USD","IE00BWXC8680.SGD","BK4533","SG9999001176.SGD","LU1623119135.USD","LU0133085943.USD","IE00B4R5TH58.HKD","LU0158827781.USD","LU0640476718.USD","LU0672654240.SGD","SG9999013999.USD","IE0009355771.USD","LU0122379950.USD","SG9999015978.USD","SGXZ31699556.SGD","LU2468319806.SGD","LU0353189680.USD","LU2236285917.USD","LU1868836914.USD","IE00BKDWB100.SGD","LLII","BK4588","LU0354030511.USD","LU1093756168.USD","ELIL","LU2471134879.HKD","LU1917777945.USD","LU0256863811.USD","LU0094547139.USD","LU2491050071.SGD","LU0889565916.HKD","LU0316494557.USD","LU1291159041.SGD","LU2552382058.USD","LU0256863902.USD","SG9999014880.SGD","LU0289739699.SGD","IE00BK4W5L77.USD","LU0471298694.HKD","BK4534","LU2237443978.SGD","IE00BJJMRX11.SGD","LU2089284900.SGD","SG9999014914.USD","LU1868836591.USD","LU1868837136.USD","IE00BJJMRZ35.SGD","LU1983299246.USD","LU2168564149.EUR","LU2471134523.USD","SGXZ99366536.SGD","LU2028103732.USD","LU2111349929.HKD","LU2264538146.SGD","LU0882574055.USD","LLYZ","IE0004445239.USD","IE00B7KXQ091.USD","LU0823434740.USD","LU0058720904.USD","LU2237443549.SGD","LU2750360641.GBP","LU1548497426.USD","LU2168564222.USD","LU2756315318.SGD","SG9999015952.SGD","ELIS","LU2456880835.USD","LU1551013425.SGD","LU0106261372.USD","LU0061475181.USD","LU1814569148.SGD","LU2361045086.USD","SG9999015945.SGD","LU2471134796.USD","LU2756315664.SGD","BK4599","LU0266013472.USD","LU2750360997.AUD","LU2063271972.USD","LU2211815571.USD","LU0320765992.SGD","LLYX","LU0323591593.USD","IE00BN29S564.USD","IE00B775H168.HKD","SGXZ81514606.USD","IE00BFTCPJ56.SGD","LU2237443895.HKD","LU0820561818.USD","LU0198837287.USD","SG9999001176.USD","LU0006306889.USD","LU0238689110.USD","BK4585","LU0432979614.USD","LU1057294990.SGD","IE00B2B36J28.USD","LU2023250504.SGD","LU2168563687.JPY","SG9999015986.USD","LU1093756325.SGD","LU2168564065.EUR","SG9999018865.SGD","IE00BKPKM429.USD","LU2023251221.USD","BK4516","LU0109391861.USD","LU0823434583.USD","LU2213496289.HKD","LU0689472784.USD","LU2265009873.SGD","LU2417539215.USD","BK4581","LU2271345857.HKD","LU0964807845.USD","LU2112291526.USD","LU1232071149.USD","LU1720051108.HKD","LU2491050154.USD","LU2087625088.SGD","LU1267930730.SGD","LU1551013342.USD","LU1988902786.USD","SG9999018857.SGD","LU2324357040.USD","IE00BFSS8Q28.SGD","LU1989771016.USD","LU2106854487.HKD","GB00BDT5M118.USD","LU0097036916.USD","LU0109394709.USD","IE00B4JS1V06.HKD","LU2237443382.USD","LU1629891620.HKD","LU2602419157.SGD","LU2471134952.CNY","LU1720051017.SGD","LU2108987350.USD","IE0004445015.USD","LU1804176565.USD","LU0234572021.USD","SG9999017495.SGD","SGXZ57979304.SGD","SG9999014898.SGD","LU0353189763.USD","LU0786609619.USD","LU2089283258.USD","BK4148","LU2361044865.SGD","LU1127390331.HKD","LU2237438978.USD","IE00BK4W5M84.HKD","LU0385154629.USD","LU0943347566.SGD","LU2360106947.USD","LU2357305700.SGD","LU2461242641.AUD","LU0708995401.HKD","LU1064131342.USD","LU2168564495.EUR","LU2361044949.HKD","IE00B1XK9C88.USD","LU0466842654.USD","IE00BJLML261.HKD","LU0096364046.USD","LU0158827948.USD","LU0203201768.USD","LU2746668974.SGD","AKTS","LU1366192091.USD","LU1868836757.USD","LU0320765059.SGD","BK4139","LU1035775433.USD","LU0354030438.USD","LU0417517546.SGD","LU0471298777.SGD","LU0079474960.USD","SG9999014906.USD","SGXZ51526630.SGD","LU0820561909.HKD","LU0456855351.SGD","LU1868837300.USD","BK4007","IE0005OL40V9.USD","LU2023250330.USD","LU2746668461.USD","LU2237443465.HKD","IE0002141913.USD","IE0001KFT4U8.USD","LU0203202063.USD","LU1061106388.HKD","LU0787776722.HKD","LU1974910355.USD","LU1323610961.USD","LU2552382215.SGD","LU0225283273.USD","LU0882574139.USD","LU0114720955.EUR","LU2089984988.USD","LU2491049909.HKD","LU2552382132.HKD","LU2896262040.SGD","IE00BFSS7M15.SGD","LU2462157665.USD","LU0210536198.USD","LU0683600562.USD","IE00BJT1NW94.SGD","LU1712237335.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634232655","title":"Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2634232655","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634232655?lang=en_us&edition=fundamental","pubTime":"2026-05-12 04:01","pubTimestamp":1778529660,"startTime":"0","endTime":"0","summary":"Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segmentsInitiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/11/3292282/0/en/Aktis-Oncology-Reports-Financial-Results-and-Business-Highlights-for-First-Quarter-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4148","AKTS","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633336831","title":"Aktis Oncology to Present at the BofA Securities Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2633336831","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633336831?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:00","pubTimestamp":1778068800,"startTime":"0","endTime":"0","summary":"BOSTON, May  06, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmac","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3288736/0/en/Aktis-Oncology-to-Present-at-the-BofA-Securities-Health-Care-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4585","BK4581","AKTS","BK4139","BK4148","BK4588","XLV","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aktisoncology.com","stockEarnings":[{"period":"1week","weight":0.0763},{"period":"1month","weight":0.5857},{"period":"3month","weight":0.7784},{"period":"6month","weight":0.7161},{"period":"ytd","weight":0.7161}],"compareEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":-0.0168},{"period":"3month","weight":0.1371},{"period":"6month","weight":0.0916},{"period":"1year","weight":0.2074},{"period":"ytd","weight":0.0936}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., designs, develops, manufactures, and sells radio frequency (RF) filter products for the wireless industry in the Americas, Asia, Europe, and internationally. It operates in two segments, Fabrication Services and RF Filters. The Fabrication Services segment provides engineering review and backend packaging services. The RF Filters segment sells amplifier and filter products. It offers RF filters for the wireless industry, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense applications. The company also sells complementary surface acoustic wave resonators, crystal (Xtal) resonators and oscillators, and ceramic products; and provides back-end semiconductor supply chain services. Akoustis Technologies, Inc. is headquartered in Huntersville, North Carolina.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.07242},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.009578},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.089105},{"month":4,"riseRate":0.25,"avgChangeRate":-0.011983},{"month":5,"riseRate":0.5,"avgChangeRate":-0.07198},{"month":6,"riseRate":0.5,"avgChangeRate":-0.041124},{"month":7,"riseRate":0.25,"avgChangeRate":-0.065017},{"month":8,"riseRate":0.5,"avgChangeRate":-0.046698},{"month":9,"riseRate":0.375,"avgChangeRate":-0.092023},{"month":10,"riseRate":0.375,"avgChangeRate":-0.160528},{"month":11,"riseRate":0.625,"avgChangeRate":0.149228},{"month":12,"riseRate":0.375,"avgChangeRate":0.01269}],"exchange":"NASDAQ","name":"Aktis Oncology","nameEN":"Aktis Oncology"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aktis Oncology(AKTS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aktis Oncology(AKTS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aktis Oncology,AKTS,Aktis Oncology股票,Aktis Oncology股票老虎,Aktis Oncology股票老虎国际,Aktis Oncology行情,Aktis Oncology股票行情,Aktis Oncology股价,Aktis Oncology股市,Aktis Oncology股票价格,Aktis Oncology股票交易,Aktis Oncology股票购买,Aktis Oncology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aktis Oncology(AKTS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aktis Oncology(AKTS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}